RATIONALE: We previously demonstrated that the addition of the selective norepinephrine reuptake inhibitor reboxetine attenuates olanzapine-induced weight gain. Using the same study sample, we also sought to determine whether reboxetine's weight-attenuating effect was accompanied by a beneficial effect on metabolic and endocrine parameters relevant to antipsychotic-induced weight gain and obesity. METHOD: Blood samples at baseline and at the end of the 6-week trial were available for 54 participants who participated in previous double-blind, placebo-controlled studies of reboxetine (4 mg BID) addition to olanzapine-treated schizophrenia patients. Fasting glucose, lipid profile, insulin, leptin, cortisol, dehydroepiandrosterone (DHEA), prolactin, and thyroid-stimulating hormone (TSH) were analyzed. RESULTS: In contrast to the olanzapine/placebo group, the olanzapine/reboxetine group exhibited a reduction in blood triglyceride (p < 0.05) and leptin (p < 0.05) levels, and elevation in cortisol (p < 0.05) and DHEA (p < 0.008) levels. No significant between-group differences were detected in the changes in cholesterol, glucose, insulin, TSH, and prolactin. CONCLUSIONS:Reboxetine addition resulted in meaningful improvement of some metabolic and endocrine measures associated with olanzapine-induced weight gain. The potential role of reboxetine in the prevention of olanzapine-induced weight gain and cardio-metabolic morbidity merits further large-scale, long-term investigation.
RCT Entities:
RATIONALE: We previously demonstrated that the addition of the selective norepinephrine reuptake inhibitor reboxetine attenuates olanzapine-induced weight gain. Using the same study sample, we also sought to determine whether reboxetine's weight-attenuating effect was accompanied by a beneficial effect on metabolic and endocrine parameters relevant to antipsychotic-induced weight gain and obesity. METHOD: Blood samples at baseline and at the end of the 6-week trial were available for 54 participants who participated in previous double-blind, placebo-controlled studies of reboxetine (4 mg BID) addition to olanzapine-treated schizophreniapatients. Fasting glucose, lipid profile, insulin, leptin, cortisol, dehydroepiandrosterone (DHEA), prolactin, and thyroid-stimulating hormone (TSH) were analyzed. RESULTS: In contrast to the olanzapine/placebo group, the olanzapine/reboxetine group exhibited a reduction in blood triglyceride (p < 0.05) and leptin (p < 0.05) levels, and elevation in cortisol (p < 0.05) and DHEA (p < 0.008) levels. No significant between-group differences were detected in the changes in cholesterol, glucose, insulin, TSH, and prolactin. CONCLUSIONS:Reboxetine addition resulted in meaningful improvement of some metabolic and endocrine measures associated with olanzapine-induced weight gain. The potential role of reboxetine in the prevention of olanzapine-induced weight gain and cardio-metabolic morbidity merits further large-scale, long-term investigation.
Authors: Rael D Strous; Rafael Stryjer; Rachel Maayan; Gilad Gal; Dina Viglin; Elena Katz; Dana Eisner; Abraham Weizman Journal: Psychoneuroendocrinology Date: 2007-01-08 Impact factor: 4.905
Authors: Rael D Strous; Rachel Maayan; Raya Lapidus; Rafael Stryjer; Michal Lustig; Moshe Kotler; Abraham Weizman Journal: Arch Gen Psychiatry Date: 2003-02
Authors: Johanna Taylor; Brendon Stubbs; Catherine Hewitt; Ramzi A Ajjan; Sarah L Alderson; Simon Gilbody; Richard I G Holt; Prakash Hosali; Tom Hughes; Tarron Kayalackakom; Ian Kellar; Helen Lewis; Neda Mahmoodi; Kirstine McDermid; Robert D Smith; Judy M Wright; Najma Siddiqi Journal: PLoS One Date: 2017-01-05 Impact factor: 3.240
Authors: Pruntha Kanagasundaram; Jiwon Lee; Femin Prasad; Kenya A Costa-Dookhan; Laurie Hamel; Madeleine Gordon; Gary Remington; Margaret K Hahn; Sri Mahavir Agarwal Journal: Front Psychiatry Date: 2021-03-17 Impact factor: 4.157
Authors: Petter Andreas Ringen; John A Engh; Astrid B Birkenaes; Ingrid Dieset; Ole A Andreassen Journal: Front Psychiatry Date: 2014-09-26 Impact factor: 4.157